17:21 , May 3, 2018 |  BC Extra  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million in a follow-on Thursday through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright & Co. and...
18:02 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

uniQure maps plan for hemophilia B gene therapy

uniQure N.V. (NASDAQ:QURE) rose 60% on Oct. 19 after the company said it will begin a Phase III trial next year of gene therapy AMT-061 to treat hemophilia B. The adeno-associated viral serotype 5 (AAV5)...
21:56 , Oct 19, 2017 |  BC Extra  |  Clinical News

uniQure maps plan for hemophilia B gene therapy

uniQure N.V. (NASDAQ:QURE) rose $5.69 (60%) to $15.16 after it said it will begin a Phase III trial next year of gene therapy AMT-061 to treat hemophilia B. The adeno-associated viral serotype 5 (AAV5) vector's...
19:46 , Aug 3, 2017 |  BioCentury  |  Emerging Company Profile

Tunable cell therapies

Sigilon Therapeutics Inc. is developing allogeneic cell therapy implants for protein deficiency disorders that thread the needle between protein replacement therapies that require frequent dosing, and gene and cell therapies that are hard to dose-adjust....
00:26 , Apr 15, 2017 |  BioCentury  |  Product Development

Outside factors

This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades....
19:02 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hemophilia Mouse studies suggest nanoparticles loaded with Factor IX mRNA could help treat hemophilia. The nanoparticles consisted of an ionizable lipid, cholesterol and PEG ( Arcturus Therapeutics Inc. 's LUNAR nanoparticle system) loaded with...
02:38 , Feb 11, 2017 |  BioCentury  |  Strategy

Building Bioverativ

Biogen Inc. ’s newly minted hematology spinout Bioverativ Inc. will have at least three years to build market share for its hemophilia therapies and flesh out its pipeline before gene therapies potentially hit the market....
00:02 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

AMT-060 regulatory update

FDA granted breakthrough therapy designation to AMT-060 from uniQure to treat hemophilia B. The company said the designation is based on data from an ongoing, open-label, European Phase I/II trial of AMT-060 in patients with...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
23:50 , Nov 15, 2016 |  BC Extra  |  Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR...